Please ensure Javascript is enabled for purposes of website accessibility

MannKind Corporation Is Moving Higher Again -- Here's Why

By Brian Feroldi - Jan 14, 2016 at 2:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A presentation at the JP Morgan Healthcare Conference gave its investors a reason to cheer.

What: Investors in MannKind Corporation (MNKD 0.93%) are having another good day. Shares are up more than 10% as of 2:00 p.m. ET as investors cheered the company's presentation at the JP Morgan Healthcare Conference.

So what: The stock is continuing its rebound from a huge sell-off earlier in the month as news broke that marketing partner Sanofi (SNY 1.08%) was terminating its contract to commercialize Afrezza, MannKind's inhaled insulin. 

The company is still finalizing plans for how to proceed from here, but it did give investors a list of near-term priorities during the presentation, which included:

  • Find a new partner to help commercialize Afrezza now that Sanofi is out of the picture
  • Develop patient and provider advocacy channels, including its new "Afrezza Advocacy Council," to help build awareness for Afrezza at a low cost
  • Continuing exploring new applications for its Technosphere technology and sign a new partner as quickly as possible
  • Developing plans to launch Afrezza by itself in case no one is willing to step in to fill Sanofi's vacancy
  • Sell its California facility, which it believes will bring in roughly $23 million

This rough plan was enough to get shares moving in the right direction.

Now what: It's unknown if a new partner will step up to the plate to either to help MannKind commercialize Afrezza or explore new product candidates to utilize its inhaled drug-delivery technology. However, the company did provide investors with a look at all the product candidates that it is considering:

Data source: MannKind's JP Morgan presentation.

Its management team seems particularly excited about epinephrine as a product candidate as it believes the development timeline would be "incredibly short."

As for its financial position, MannKind's management stated that at current spending levels, it has enough cash on hand to fund itself into the second half of 2016 and it is implementing "aggressive financial controls" to extend that runway out even further. It also hinted that it might be able to negotiate a fee from Sanofi as it brings the sales and marketing of Afrezza back in-house. Add in a potential cash infusion from the sale of its California facility and the company believes that it has enough time to right the ship.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$49.71 (1.08%) $0.53
MannKind Corporation Stock Quote
MannKind Corporation
$4.33 (0.93%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.